Harvard's Demetri on Bayer Regorafenib Cancer Drug

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

June 4 (Bloomberg) -- George Demetri, an associate professor at Harvard University Medical School, talks about Bayer AG’s experimental cancer drug regorafenib. He spoke with Bloomberg's Shannon Pettypiece at the American Society of Clinical Oncology meeting in Chicago. (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change